Compare Ascendis Pharma A/S (ASND) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Tenet Healthcare Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Tenet Healthcare Corporation trades at $204.25 (market cap $17.59B). The key difference: Ascendis Pharma A/S and Tenet Healthcare Corporation are close in size by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | THC | |
|---|---|---|
Market Cap | $17.74B | $17.59B |
Sector | Health | Health |
52-Week High | $277.18 | $244.80 |
52-Week Low | $163.32 | $148.38 |
Enterprise Value | $18.11B | $27.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Tenet Healthcare (THC) trades at $204.25, down 1.22% amid broader market weakness. The stock maintains strong fundamentals with a P/E of 10.62 and robust profitability metrics including 37.87% ROE. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show bullish momentum despite overbought RSI readings, with support at $204 and resistance at $209.
The outlook remains positive with 81% analyst buy ratings and a $233.63 consensus price target representing 14% upside. Key risks include healthcare regulatory pressures and execution challenges in outpatient expansion. Earnings growth from the Ambulatory Care segment and defensive positioning during geopolitical tensions provide catalysts for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
